

Human IL 12/23 (Briakinumab) Antibody

Biosimilar Recombinant Human Monoclonal Antibody

Product Information

Product No.: LT500

Clone: ABT-874

Isotype: AB_2893961

RRID: Human IgG1 λ

Storage: Sterile 2° to 8°C

Product Description

Specificity:

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.

Antigen Distribution:

IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.

Background:

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23 α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Known Reactivity Species:

Human

Expression Host:

HEK-293 Cells

Format:

Purified No Carrier Protein

Immunogen:

This antibody was produced by phage display technology.

Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Purity

≥95% by SDS Page, ≥95% monomer by analytical SEC

Endotoxin

< 1.0 EU/mg as determined by the LAL method

Storage and Stability

Functional grade preclinical antibodies may be stored sterile as received at 2° to 8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C.

Avoid Repeated Freeze Thaw Cycles

Do not freeze

Applications

Applications and Recommended Usage (Quality Tested By Leinco):

FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 µg per 10⁶ cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.

ELISA

Other Applications Reported in Literature:

FA

Country of Origin

USA

References

- 1) Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123